EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tengion's Enterprise Value is $0.00 Mil.
Tengion's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2014 was $-19.25 Mil. Therefore, Tengion's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Tengion's EV-to-FCF or its related term are showing as below:
TNGNQ's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.375 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-06), Tengion's stock price is $0.0001.
Tengion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2014 was $-0.920. Therefore, Tengion's PE Ratio for today is At Loss.
Tengion EV-to-FCF Historical Data
The historical data trend for Tengion's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tengion's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tengion's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tengion's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tengion's EV-to-FCF falls into.
Tengion's current Enterprise Value is $0.00 Mil.
Tengion's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tengion (GREY:TNGNQ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tengion's share price for today is $0.0001.
Tengion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tengion EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Tengion's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNGNQ has been successfully added to your 